Pharmas love to pile on to one idea hoping for the next big thing. That herd mentality, along with patent pressures and a declining stock of innovative late-stage biopharma assets, is leading to fierce battles to land M&A deals. Experts say intense discussions are playing out behind the scenes in addition to the public bidding wars. As soon as one buyer shows interest, the phone will start ringing. The situation has become more acute as biopharma M&A has opened up. Deal processes are getting even tougher. Sellers are fielding multiple serious inquiries and deal terms are starting to adjust, with more cash offered upfront to gain an edge.
Read the full article: Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles //
Source: https://www.biospace.com/business/pharma-is-ravenous-for-m-a-action-but-late-stage-supply-dwindles